GlassScriptPhysician profile
Chisara Adonai
NPI 1609873868
$3,557.46
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $1,659 · 2021: $795 · 2024: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $633.93 | 2019-2021 | |
| Gilead Sciences, INC. | $294.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $252.66 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.51 | 2019-2021 | |
| Lilly USA, LLC | $186.31 | 2019-2024 | Jardiance |
| Stryker Corporation | $168.58 | 2024 | Mako |
| Allergan, INC. | $164.54 | 2019-2020 | |
| Novo Nordisk INC | $136.83 | 2019-2024 | Ozempic |
| Pfizer INC. | $133.15 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.48 | 2020-2024 | Xifaxan |
| Abbvie INC. | $119.65 | 2021 | |
| Merck Sharp & Dohme LLC | $116.89 | 2019-2020 | |
| Amgen INC. | $113.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.07 | 2019-2020 | |
| Astellas Pharma US INC | $102.11 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $93.68 | 2019-2020 | |
| Orexo US, INC. | $62.01 | 2019-2020 | |
| Optinose US, INC. | $57.79 | 2020-2021 | |
| Amarin Pharma, INC. | $49.91 | 2020 | |
| Ibsa Pharma INC. | $49.88 | 2020 | |
| Eisai INC. | $45.60 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $40.15 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $36.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $30.46 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $29.64 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.81 | 2020-2021 | |
| Esperion Therapeutics, INC. | $26.89 | 2020 | |
| Radius Health, INC. | $21.86 | 2024 | |
| Antares Pharma, INC. | $21.37 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.82 | 2021 | |
| Global Blood Therapeutics, INC. | $16.59 | 2021 | |
| Therapeuticsmd, INC. | $15.65 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.48 | 2019 | |
| Bausch Health US, LLC | $11.59 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chisara Adonai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.